Immunogenicity of oral polio vaccine in different doses in Mozambique

• Conditions: poliomyelitis; Infection - Other infectious diseases

• Registration Number: ACTRN12619000184178
• Lead Sponsor: WHO

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2019-02-08
• Last Update Posted: 15 July 2019

Recruitment & Eligibility

• Status: ot yet recruiting
• Sex: All
• Target Recruitment: 360

Inclusion Criteria

healthy child between 9-22 months of age living in study area

Exclusion Criteria

no consent
residence outside of study area
known immunodeficiency

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Seroconversion after one full or reduced dose of mOPV2 expressed by increase in poliovirus type 2 antibodies assessed by neutralization assay test of sera[Comparison of proportion of children who seroconverted 14 days after one or two drops of mOPV2 vaccine]

Secondary Outcome Measures

Name	Time	Method
Titre of poliovirus type 2 neutralizing antibodies after one or two drops of mOPV2 assessed by neutralization assay test of sera[14 days after intervention]